Argenica Therapeutics (AGN) Q4 2026 TU earnings summary

Executive summary

• Advanced preparations for a late-stage clinical trial in moderate to severe acute ischaemic stroke (AIS) patients, with a global Clinical Advisory Committee convened to optimize trial design and leverage precision medicine strategies for enrolment and success probability.

• Completed three FDA-requested safety assays (hERG, TNK, genotox), all showing clean and favorable safety profiles, positioning for IND submission and potential US trial commencement.

• WHO confirmed the International Nonproprietary Name (INN) xaranetide for ARG-007, the lead neuroprotective drug candidate.

• Xaranetide demonstrated significant neuroprotection in a preclinical concussion study, supporting its development across a spectrum of traumatic brain injury models.

• Two abstracts from the Phase 2 trial were presented at the European Stroke Organisation Conference, increasing clinical and scientific engagement.

Financial highlights

• Cash reserves stood at $6.35 million as of 30 June 2026, supporting ongoing trial preparations.

• Net operating cash outflows for the quarter were $1.605 million, with R&D expenditure at $0.995 million, staff costs at $0.432 million, and corporate administration at $0.199 million.

• Received non-dilutive funding, including up to $1.5 million from the MRFF TTRA program and over $4 million in grants and philanthropic funding to support clinical and preclinical projects.

• Eligible for an R&D tax incentive cash rebate on FY26 expenditure, with submissions underway.

Outlook and guidance

• Finalization of the late-stage trial protocol and submission to the FDA expected in Q3 CY2026, with feedback anticipated before quarter-end.

• The late-stage trial will focus on moderate to severe AIS, leveraging AI-enabled diagnostic tools for patient selection and aiming for a Phase 2b or seamless Phase 2b/3 design.

• Sufficient funding for approximately four quarters of operations at current cash burn rates.